The Hormone Replacement Therapy (HRT) market is estimated to represent a global market of USD 20.97 billion by 2019 with growth rate of 7.5%.
Market Dynamics
Menopause is a natural and inevitable event, defined as the final menstrual period. It requires a retrospective clinical diagnosis with ethnic and regional variations. Hormone replacement therapies (HRT) such as systemic estrogen (skin patch, gel, or cream) are considered to be the most effective treatment option in the treatment of menopausal night sweats and hot flashes. These therapies also ease vaginal symptoms of menopause such as itching, burning, and dryness. Due to this fact, women undergoing these therapies has increased considerably over the past few years.
As per the Rose Research Survey (April 2014), women accepting HT therapy has increased considerably, from 4.5 million in 2005 to around 5.0 million in 2014. In addition to this, the growth of this market is attributed to the rise in a number of women in menopausal age coupled with growing patient awareness. For example, according to the International Menopause Society, thousands of women reach menopause experience every day. On another hand, the high cost of therapies coupled with the high risk of adverse reactions posing a potential threat to this industry. For example, as per the study published in PLOS One journal in 2014, testosterone therapy in cardiac patients considerably increase the risk of heart attack.
Replacement Therapy Takeaway
In terms of replacement therapy, the market is categorized as Estrogen, Human Growth Hormone, Testosterone and Thyroid. Estrogen replacement therapy recorded USD 9.58 billion and is expected to soar owing to the approval of new products by the United States Food and Drug Association under this category. Some of the recommended estrogen doses for women with Primary Ovarian Insufficiency (POI) are 1.25 mg conjugated equine estrogen (CEE), 17b-estradiol 2 mg/day, and transdermal estradiol 75–100 mg/day.
Furthermore, Climara, Estradot, Divigel, Elestrin, and EstroGel are some of the commercially available transdermal estrogen products in the U.S. and Canada market by various manufacturers. On contrary, thyroid replacement therapy is considered to be the lowest revenue generating segment and is also pegged to register slowest growth rate i.e. 6.9% in terms of value. Levothyroxine (generic form of thyroxine) is a most commonly prescribed thyroid hormone replacement drug across the globe.
Cumulative effect of COVID-19
As players move from reacting to mitigating the impact of the COVID-19 outbreak, they are keenly focusing on Hormone Replacement Therapy (HRT) market offers detailed analysis on the emerging market player during this outbreak. The report also included the detailed study related to impact of COVID-19 on the supply chain based on both downstream and upstream markets. The report also includes the future development in the Hormone Replacement Therapy (HRT) Market in relation with the market impact of COVID-19.
Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-53287
Regional Takeaway
Regionally, the market is divided into North America, Europe, Asia Pacific and Rest of the World. Of these, North America captured the highest share, 41.67% of the total market. Drugs such as Premarin, AndroGel, and Levothyroxine have been recorded to gain the maximum prescription within this region. However, Asia Pacific region represents one of the fastest growing regions, enjoying an annual average growth rate over 9.0%. Rising awareness levels coupled with increasing focus of healthcare and government on eradication of hormonal deficiencies are likely to establish a healthy platform for the industry growth in this region.
Key Vendor Takeaway
Companies such as Novo Nordisk, Amgen, Inc., Abbott, Eli Lily and Genentech are covered under research study. The industry experiences a high level of competition. In such fragmented landscape, key players are actively engaged in strategic collaborations to expand their market presence. For instance, in February 2015, Mylan Laboratories signed an agreement for the acquisition of Famy Care.
This acquisition has helped the company to increase its female health product portfolio inclusive of production of hormone replacement drugs, Intra-Uterine Devices (IUD), and contraceptives. Likewise, in December 2014, Pfizer collaborated with OPKO Health. As per the agreement, OPKO would be developing and marketing long-acting human growth hormone (hGH-CTP) (PF-06836922), whereas Pfizer would take care of the post-market studies and development costs.
The market size and forecast for each segment has been provided for the period 2016 to 2027, considering 2019 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2021 to 2027 for every reported segment.
The years considered for the study are:
Historical Year – 2016 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2027
The proposed reports analyse and evaluates the COVID-19 Impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
HORMONE REPLACEMENT THERAPY (HRT) MARKET, BY REPLACEMENT THERAPY
Estrogen
Human Growth Hormone
Testosterone
Thyroid
HORMONE REPLACEMENT THERAPY (HRT) MARKET, BY ROUTE OF ADMINISTRATION
Parenteral
Oral
Transdermal
Other
HORMONE REPLACEMENT THERAPY (HRT) MARKET, BY DISEASE
Male Hypogonadism
Menopause
Hypothyroidism
Growth Hormone Deficiency
Others
HORMONE REPLACEMENT THERAPY (HRT) MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.
For more information, please contact:Hina Miyazu
Shibuya Data Count
Email: sales@sdki.jp
Tel: + 81 3 45720790
Related Posts:
Enteral Feeding Devices Market
Fertilization Technique Market
Artificial Insemination Market
Medical Oxygen Concentrators Market
Assisted Reproductive Technology (ART) Market
U.S. Pharmacy Benefit Management (PBM) Market
Magnetic Resonance Imaging Market
Infectious Diseases In Vitro Diagnostics Market
